A Clinicobiological Database in Metastatic Digestive Cancers
Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers
Institut du Cancer de Montpellier - Val d'Aurelle
200 participants
Sep 12, 2016
INTERVENTIONAL
Conditions
Summary
Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.
Eligibility
Inclusion Criteria4
- Male or female ≥ 18 years old
- Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus
- Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy
- Informed consent form (ICF) signed
Exclusion Criteria7
- Male or female \< 18 years old
- Non-adenocarcinoma histological type
- Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line
- Pregnant and/or breastfeeding woman
- Patient not affiliated to a social security system
- Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons
- Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples
Interventions
\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03978078